[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100208117":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":25,"centralContacts":30,"locations":35,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":68,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Maastricht Radiation Oncology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"H&N cancer patients",null,"Patients with Head and Neck Cancer, treated with curative intent\n\n* Any tumor site\n* Stage I-IV, M0\n* Treated with radiotherapy alone or in combination with systemic therapy\n* Definitive radiotherapy or postoperative radiotherapy\n\nInterventions:\n\n* Radiation alone\n* Radiation in combination with systemic therapy",[13,14],"Radiation: Radiation alone","Radiation: Radiation in combination with systemic therapy",[16,20],{"type":17,"name":18,"description":18,"armGroupLabels":19,"otherNames":10},"RADIATION","Radiation alone",[9],{"type":17,"name":21,"description":21,"armGroupLabels":22,"otherNames":23},"Radiation in combination with systemic therapy",[9],[24],"Chemoradiation",[26],{"name":27,"affiliation":28,"role":29},"F Hoebers, MD, PhD","Maastro Clinic, The Netherlands","PRINCIPAL_INVESTIGATOR",[31],{"name":27,"role":32,"phone":33,"phoneExt":10,"email":34},"CONTACT","+31884455666","frank.hoebers@maastro.nl",[36],{"facility":37,"status":38,"city":39,"state":10,"zip":10,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Maastro Clinic","RECRUITING","Maastricht","Netherlands","NL",{"type":43,"coordinates":44},"Point",[45,46],5.68889,50.84833,{"lat":46,"lon":45},[49,51],{"name":50,"role":32,"phone":10,"phoneExt":10,"email":10},"Ph Lambin, prof Dr",{"name":52,"role":29,"phone":10,"phoneExt":10,"email":10},"Frank Hoebers, Dr.",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100208117","outcome-prediction-in-headneck-cancer-patients-after-radiotherapy-100208117",false,"NCT01985984","Outcome Prediction in Head&Neck Cancer Patients After Radiotherapy","Outcome Prediction in Head&Neck Cancer Patients After Radiotherapy Using Multi-parameter Modelling: Disease Control, Toxicity and Quality of Life","OutcomeH&N","Inclusion Criteria:\n\nAll patients planned for curatively intended primary or postoperative radiotherapy\n\nExclusion Criteria:\n\nAll patients planned for palliative radiotherapy","ALL","18 Years",{"count":66,"type":67},1000,"ESTIMATED","5 Years","OBSERVATIONAL","The primary and general objective of the clinical introduction of the Standard Follow-up Program (SFP) as the current standard of care is to improve the quality of radiotherapy for head and neck cancer patients by reducing radiation-induced side effects without hampering treatment efficacy in terms of locoregional tumour control and overall survival and to systematically evaluate the beneficial effect of newly introduced radiation technology for this particular group of patients. The clinical introduction of the SFP will allow for a systematic and broad scale quality improvement cycle for head and neck cancer patients treated with radiotherapy. In fact, this methodology can be considered a kind of quality circle for the clinical introduction of new radiation techniques, aiming at continuous efforts for further improvement.",[72],"Head and Neck Cancer",[74],"Head and neck cancer","2025-08-11",{"date":77,"type":78},"2025-08-14","ACTUAL",{"date":80,"type":10},"2012-07",{"date":82,"type":67},"2030-01",{"name":5,"class":6},1]